Boehringer Ingelheim Canada has finished negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) — a partnership between the country’s provincial, territorial and federal governments — for Ofev (nintedanib), the company’s approved oral medication for progressive fibrosing interstitial lung diseases (PF-ILD). The pCPA conducts negotiations with drug manufacturers for treatments…
Ofev Negotiations Complete in Canada, Paving Way for Availability
During the course of having idiopathic pulmonary fibrosis (IPF) or any other rare disease, the role of the caregiver requires a large measure of patience, an ability to multitask, and the capability to pivot without knowing what lies ahead. Caregivers, whether working alone or as part of a team,…
C21 (VP01), Vicore Pharma’s investigational oral therapy, safely and effectively improves or stabilizes lung function in previously untreated adults with idiopathic pulmonary fibrosis (IPF), according to interim data from the open-label Phase 2 AIR trial. “Based on the mechanism of action of C21, which has both vascular and…
An analysis of gene activity profiles in lung tissue has identified important drivers of idiopathic pulmonary fibrosis (IPF). The genes discovered in this integrative analysis may predict disease outcomes and be used as potential therapeutic targets for new anti-fibrotic treatments, according to researchers. The study, “Integrative…
Since 2008, Rare Disease Day — the last day of February — has brought together patients, caregivers, family members, friends, and advocates from around the world to raise awareness and improve equity for the more than 7,000 known rare diseases that affect more than 300 million people. In 2022, the…
A novel imaging biomarker identified via an artificial intelligence (AI)-powered analysis could help predict lung function and survival outcomes for people with idiopathic pulmonary fibrosis (IPF). Brainomix, a U.K.-based software company, is developing a number of AI-based tools to analyze different diseases, including one called e-ILD…
Endeavor BioMedicines has raised $101 million to advance its pipeline programs, including taladegib (ENV-101), an investigational oral treatment for idiopathic pulmonary fibrosis (IPF) now in a clinical trial, and for cancer linked to mutations in the PTCH1 gene. The funding was the result of a series B…
Teaching has been a passion of mine since I earned my masters degree in sociology from the University of Houston-Clear Lake (UHCL) in 2013. Becoming a college professor gave me a sense of self-worth. I was proud of my accomplishments, especially since I obtained my degree so late in…
Is 90% of a message’s effectiveness dependent upon the way it is delivered? In terms of our rare disease, how important are the words we use to describe it? Many of us with a rare disease only learned about it when we were diagnosed, so we shouldn’t be surprised…
The more monocyte immune cells that circulate in a person’s bloodstream, the greater the odds that lung abnormalities, such as those linked to pulmonary fibrosis, will show up on a CT imaging scan, a study found. Researchers also observed that a higher monocyte count increased the odds of lung…
